ArticleNature genetics2018
Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.
Open access · greenAbstract read
In one paragraph
Article in Nature genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 129 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
129citing papers in PubMed, 1 pooled it
26.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
129 citing papers in PubMed, 1 synthesis or guideline pooled it, 234 citations in OpenAlex.
- Efficacy and safety of metastasis-directed therapy for oligometastatic cancer: a systematic review and meta-analysis of randomized controlled trials.Radiation oncology (London, England) · 2026Pooled it
- Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2021Trial
- Genomics of lethal prostate cancer at diagnosis and castration resistance.The Journal of clinical investigation · 2020Trial
- The molecular heterogeneity and clinical impact of genomic driver alterations in prostate cancer.Nature communications · 2026Article
- Recurrent mechanisms of biallelic epigenetic inactivation reveal new putative tumour suppressor genes in prostate cancer.Nature communications · 2026Article
- Article
- Mechanisms of Progression and Challenges for Intervention in the Natural History of Early Prostate Cancer: A Narrative Review.Current oncology (Toronto, Ont.) · 2026Review
- Single-cell genomic analysis of cancer cells from one treatment-naïve patient with metastatic prostate cancer.BMC genomic data · 2026Article
- Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols.Future oncology (London, England) · 2026Article
- Pan-cancer bone metastasis atlas at single-cell resolution identifies a distinct tumor-associated macrophage subset for mediating Denosumab-induced immunosensitization in lung cancer bone metastasis.International journal of biological sciences · 2026Article
- Toward the genetic landscape of prostate cancer in India: insights from whole-exome and low-pass whole-genome sequencing of formalin-fixed paraffin-embedded tumor tissues.Frontiers in systems biology · 2026Article
- Pathogenic variants reveal candidate genes for prostate cancer germline testing for men of African ancestry.Nature communications · 2025Article
- Article
- Systems biology successes and areas for opportunity in prostate cancer.Endocrine-related cancer · 2025Review
- Colibactin Exerts Androgen-dependent and -independent Effects on Prostate Cancer.European urology oncology · 2025Article
- The Germline and Somatic Origins of Prostate Cancer Heterogeneity.Cancer discovery · 2025Article
- Cyclic nucleotide phosphodiesterases as drug targets.Pharmacological reviews · 2025Review
- Genomic and transcriptomic sequencing in prostate cancer.Current opinion in oncology · 2025Review
- The landscape of NNature genetics · 2025Article
- Integrative proteogenomic profiling of high-risk prostate cancer samples from Chinese patients indicates metabolic vulnerabilities and diagnostic biomarkers.Nature cancer · 2024Article
69 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
88 authors at 18 institutions in 6 countries.
David C Wedge *Oxford Big Data Institute, University of Oxford, Oxford, UK. david.wedge@bdi.ox.ac.uk.ORCID http://orcid.org/0000-0002-7572-3196
Gunes Gundem *Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
Thomas Mitchell *Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.ORCID http://orcid.org/0000-0003-0761-9503
Dan J WoodcockOxford Big Data Institute, University of Oxford, Oxford, UK.
Inigo MartincorenaCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
Mohammed GhoriCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
Jorge ZamoraCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
Adam ButlerCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
Hayley WhitakerMolecular Diagnostics and Therapeutics Group, University College London, London, UK.
Zsofia Kote-JaraiThe Institute of Cancer Research, London, UK.
Ludmil B AlexandrovCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
Peter Van LooCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
Charlie E MassieUro-Oncology Research Group, Cancer Research UK, Cambridge Institute, Cambridge, UK.
Stefan DentroOxford Big Data Institute, University of Oxford, Oxford, UK.
Anne Y WarrenDepartment of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Clare VerrillOxford NIHR Biomedical Research Centre, Oxford, UK.
Dan M BerneyCentre for Molecular Oncology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Nening DennisRoyal Marsden NHS Foundation Trust, London and Sutton, UK.
Sue MersonThe Institute of Cancer Research, London, UK.
Steve HawkinsUro-Oncology Research Group, Cancer Research UK, Cambridge Institute, Cambridge, UK.
William HowatDepartment of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Yong-Jie LuCentre for Molecular Oncology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Adam LambertNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Jonathan KayMolecular Diagnostics and Therapeutics Group, University College London, London, UK.
Barbara KremeyerCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
Katalin KarasziNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Hayley LuxtonMolecular Diagnostics and Therapeutics Group, University College London, London, UK.
Niedzica CamachoMemorial Sloan-Kettering Cancer Center, New York, NY, USA.
Luke MarsdenNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Sandra EdwardsThe Institute of Cancer Research, London, UK.
Lucy MatthewsNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Valeria BoStatistics and Computational Biology Laboratory, Cancer Research UK Cambridge Institute, Cambridge, UK.
Daniel LeongamornlertCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
Stuart McLarenCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
Anthony NgThe Chinese University of Hong Kong, Shatin, Hong Kong, China.
Yongwei YuSecond Military Medical University, Shanghai, China.
Hongwei ZhangSecond Military Medical University, Shanghai, China.
Tokhir DadaevThe Institute of Cancer Research, London, UK.
Sarah ThomasRoyal Marsden NHS Foundation Trust, London and Sutton, UK.
Douglas F EastonCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
Mahbubl AhmedThe Institute of Cancer Research, London, UK.
Elizabeth BancroftThe Institute of Cancer Research, London, UK.
Cyril FisherRoyal Marsden NHS Foundation Trust, London and Sutton, UK.
Naomi LivniRoyal Marsden NHS Foundation Trust, London and Sutton, UK.
David NicolRoyal Marsden NHS Foundation Trust, London and Sutton, UK.
Simon TavaréStatistics and Computational Biology Laboratory, Cancer Research UK Cambridge Institute, Cambridge, UK.
Pelvender GillNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Christopher GreenmanNorwich Medical School, University of East Anglia, Norwich, UK.
Vincent KhooRoyal Marsden NHS Foundation Trust, London and Sutton, UK.
Nicholas Van AsRoyal Marsden NHS Foundation Trust, London and Sutton, UK.
Pardeep KumarRoyal Marsden NHS Foundation Trust, London and Sutton, UK.
Christopher OgdenRoyal Marsden NHS Foundation Trust, London and Sutton, UK.
Declan CahillRoyal Marsden NHS Foundation Trust, London and Sutton, UK.
Alan ThompsonRoyal Marsden NHS Foundation Trust, London and Sutton, UK.
Erik MayerRoyal Marsden NHS Foundation Trust, London and Sutton, UK.
Edward RoweRoyal Marsden NHS Foundation Trust, London and Sutton, UK.
Tim DudderidgeRoyal Marsden NHS Foundation Trust, London and Sutton, UK.
Vincent GnanapragasamDepartment of Urology, Addenbrooke's Hospital, Cambridge, UK.
Nimish C ShahDepartment of Urology, Addenbrooke's Hospital, Cambridge, UK.
Keiran RaineCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
David JonesCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
Andrew MenziesCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
Lucy StebbingsCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
Jon TeagueCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
Steven HazellRoyal Marsden NHS Foundation Trust, London and Sutton, UK.
Cathy CorbishleySt George's Healthcare NHS Trust, London, UK.
CAMCAP Study Group
Johann de BonoThe Institute of Cancer Research, London, UK.
Gerhardt AttardThe Institute of Cancer Research, London, UK.
William IsaacsJohns Hopkins School of Medicine, Baltimore, MD, USA.
Tapio VisakorpiInstitute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere, Finland.
Michael FraserPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Paul C BoutrosOntario Institute for Cancer Research, Toronto, ON, Canada.
Robert G BristowPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Paul WorkmanThe Institute of Cancer Research, London, UK.
Chris SandercBio Center, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA, USA.
TCGA Consortium
Freddie C HamdyNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Andrew FutrealCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
Ultan McDermottCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
Bissan Al-LazikaniThe Institute of Cancer Research, London, UK.
Andrew G LynchStatistics and Computational Biology Laboratory, Cancer Research UK Cambridge Institute, Cambridge, UK.ORCID http://orcid.org/0000-0002-7876-7338
G Steven BovaJohns Hopkins School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-1639-3104
Christopher S FosterUniversity of Liverpool, Liverpool, UK.
Daniel S BrewerThe Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0003-4753-9794
David E NealUro-Oncology Research Group, Cancer Research UK, Cambridge Institute, Cambridge, UK.ORCID http://orcid.org/0000-0002-6033-5086
Colin S CooperThe Institute of Cancer Research, London, UK.
Rosalind A EelesThe Institute of Cancer Research, London, UK. rosalind.eeles@icr.ac.uk.ORCID http://orcid.org/0000-0002-3698-6241
Royal Marsden NHS Foundation Trust · GBWellcome Sanger Institute · GBInstitute of Cancer Research · GBUniversity of East Anglia · GBJohns Hopkins University · USMemorial Sloan Kettering Cancer Center · USQueen Mary University of London · GBCambridge University Hospitals NHS Foundation Trust · GBCancer Research UK · GBChinese University of Hong Kong · HKHarvard University · USOntario Institute for Cancer Research · CAThe Francis Crick Institute · GBUniversity Health Network · CAUniversity of Cambridge · GBUniversity of Oxford · GBOpen Data Institute · GBSecond Military Medical University · CN
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MCancer Research UK 11566Cancer Research UK 14835Cancer Research UK 15007Cancer Research UK 17528Cancer Research UK 20406Cancer Research UK 21777Cancer Research UK 22530Cancer Research UK 22744Cancer Research UK 22897Cancer Research UK 23187Cancer Research UK 26718Cancer Research UK A11566Cancer Research UK A14835Cancer Research UK A17528Cancer Research UK A22530Cancer Research UK A23187Cancer Research UK A6743Cancer Research UK A7990NCI NIH HHS P30 CA008748Wellcome Trust
Abstract
Prostate cancer represents a substantial clinical challenge because it is difficult to predict outcome and advanced disease is often fatal. We sequenced the whole genomes of 112 primary and metastatic prostate cancer samples. From joint analysis of these cancers with those from previous studies (930 cancers in total), we found evidence for 22 previously unidentified putative driver genes harboring coding mutations, as well as evidence for NEAT1 and FOXA1 acting as drivers through noncoding mutations. Through the temporal dissection of aberrations, we identified driver mutations specifically associated with steps in the progression of prostate cancer, establishing, for example, loss of CHD1 and BRCA2 as early events in cancer development of ETS fusion-negative cancers. Computational chemogenomic (canSAR) analysis of prostate cancer mutations identified 11 targets of approved drugs, 7 targets of investigational drugs, and 62 targets of compounds that may be active and should be considered candidates for future clinical trials.
Indexed as
AdultAgedAged, 80 and overBRCA2 ProteinDisease ProgressionHepatocyte Nuclear Factor 3-alphaHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMutationOncogenesProstatic NeoplasmsBRCA2 ProteinBRCA2 protein, humanHepatocyte Nuclear Factor 3-alpha
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.